Infection Intel: Chicopee, GP Pro, US FDA, and Henry Schein

Phyllis Arthur, MBA, and David Thomas, CFA, from BIO provide insights into challenges, investment trends, and policy considerations for developing vaccines targeting rare diseases.

New research highlights long COVID’s global impact, cognitive decline, and societal consequences, urging renewed focus on prevention, including vaccination, mask use, and better air quality.

Research finds Enhanced Barrier Precautions reduce MDRO transmission in nursing homes, though challenges persist with gown usage, education, and comfort during high-contact care activities.

The rise of multidrug-resistant gonorrhea highlights the urgent need for new therapies. Zoliflodacin, a promising oral antibiotic, shows effectiveness in late-stage trials.

Novavax’s COVID-19-Influenza Combination vaccine faces a clinical hold after a trial participant developed motor neuropathy, pending further investigation by the FDA.

Paul Harleman of Vileda Professional discusses their partnership with Clean Hospitals, emphasizing innovation, sustainability, and global efforts to improve hospital hygiene and safety.